References

[1]     ICRP. ICRP Publication 80. Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. Annals ICRP 1998;28.

[2]     Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. Ann ICRP 2015;44:7–321. https://doi.org/10.1177/0146645314558019.

[3]     ICRP. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Annals ICRP 1988;18. 

[4]     ICRP. ICRP Publication 106. Radiation Dose to Patients from Radiopharmaceuticals - Addendum 3 to ICRP Publication 53. Annals ICRP 2008;38.

[5]     Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextran. J Nucl Med. 2001 Jun;42(6):951-9. PMID: 11390562.

[6]     Vidal-Sicart S, Vera DR, Valdés Olmos RA. Next generation of radiotracers for sentinel lymph node biopsy: What is still necessary to establish new imaging paradigms? Rev Esp Med Nucl Imagen Mol 2018;37:373–9. https://doi.org/10.1016/j.remn.2018.09.001.

[7]     Rovera G, de Koster EJ, Rufini V, Zollino M, Zagaria L, Giammarile F, Vidal-Sicart S, Valdés Olmos R, Collarino A. 99mTc-Tilmanocept performance for sentinel node mapping in breast cancer, melanoma, and head and neck cancer: a systematic review and meta-analysis from a European expert panel. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3375-3389. doi: 10.1007/s00259-023-06290-5. Epub 2023 Jun 13. PMID: 37310426. 

[8]     Tanis PJ, Nieweg OE, Hart AA, Kroon BB. The illusion of the learning phase for lymphatic mapping. Ann Surg Oncol. 2002 Mar;9(2):142-7. doi: 10.1007/BF02557365. PMID: 11888870.

[9]     Vidal-Sicart S, Pons F, Puig S, Ortega M, Vilalta A, Martín F, Rull R, Palou JM, Castel T. Identification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes? Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):362-6. doi: 10.1007/s00259-002-1051-7. Epub 2002 Dec 18. PMID: 12634963.

[10]     Nieweg OE, Estourgie SH. What is a sentinel node and what is a false-negative sentinel node? Ann Surg Oncol. 2004 Mar;11(3 Suppl):169S-73S. doi: 10.1007/BF02523623. PMID: 15023746. 

[11]     Moncayo VM, Alazraki AL, Alazraki NP, Aarsvold JN. Sentinel Lymph Node Biopsy Procedures. Semin Nucl Med. 2017 Nov;47(6):595-617. doi: 10.1053/j.semnuclmed.2017.06.004. Epub 2017 Sep 6. PMID: 28969759. 

[12]     Donohoe KJ, Carroll BJ, Chung DKV, Dibble EH, Diego E, Giammarile F, Grant FD, Lai SY, Linden H, Miller ME, Pandit-Taskar N, Tawa NE Jr, Vidal-Sicart S. Summary: Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema. J Nucl Med. 2023 Apr;64(4):525-528. doi: 10.2967/jnumed.123.265560. Epub 2023 Mar 23. PMID: 36958856.

[13]     Rietbergen DD, Pereira Arias-Bouda LM, van der Hage J, Valdés Olmos RA. Does99mTc-tilmanocept, as next generation radiotracer, meet with the requirements for improved sentinel node imaging? Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021;40:275-280. doi: 10.1016/j.remnie.2020.09.014.

[14]     Vidal-Sicart S, Rioja ME, Prieto A, Goñi E, Gómez I, Albala MD, Lumbreras L, León LF, Gómez JR, Campos F. Sentinel Lymph Node Biopsy in Breast Cancer with ^99mTc-Tilmanocept: A Multicenter Study on Real-Life Use of a Novel Tracer. J Nucl Med. 2021 May 10;62(5):620-627. doi: 10.2967/jnumed.120.252064.

[15]     Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. Ann ICRP 2015;44:7–321. https://doi.org/10.1177/0146645314558019.

[16]     Jimenez-Heffernan A, Ellmann A, Sado H, Huić D, Bal C, Parameswaran R, Giammarile F, Pruzzo R, Kostadinova I, Vorster M, Almeida P, Santiago J, Gambhir S, Sergieva S, Calderon A, Young GO, Valdes-Olmos R, Zaknun J, Magboo VP, Pascual TN. Results of a Prospective Multicenter International Atomic Energy Agency Sentinel Node Trial on the Value of SPECT/CT Over Planar Imaging in Various Malignancies. J Nucl Med. 2015 Sep;56(9):1338-44. doi: 10.2967/jnumed.114.153643. Epub 2015 Jul 30. PMID: 26229148.

[17]     Valdés Olmos RA, Rietbergen DDD, Rubello D, Pereira Arias-Bouda LM, Collarino A, Colletti PM, Vidal-Sicart S, van Leeuwen FWB. Sentinel Node Imaging and Radioguided Surgery in the Era of SPECT/CT and PET/CT: Toward New Interventional Nuclear Medicine Strategies. Clin Nucl Med. 2020 Oct;45(10):771-777. doi: 10.1097/RLU.0000000000003206. PMID: 32701805.

[18]     Giammarile F, Vidal-Sicart S, Paez D, Pellet O, Enrique EL, Mikhail-Lette M, Morozova O, Maria Camila NM, Diana Ivonne RS, Delgado Bolton RC, Valdés Olmos RA, Mariani G. Sentinel Lymph Node Methods in Breast Cancer. Semin Nucl Med. 2022 Sep;52(5):551-560. doi: 10.1053/j.semnuclmed.2022.01.006. Epub 2022 Mar 1. PMID: 35241267.

[19]     Giammarile F, Schilling C, Gnanasegaran G, Bal C, Oyen WJG, Rubello D, et al. The EANM practical guidelines for sentinel lymph node localisation in oral cavity squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2019;46:623–37. https://doi.org/10.1007/s00259-018-4235-

[20]     Bluemel C, Herrmann K, Giammarile F, Nieweg OE, Dubreuil J, Testori A, et al. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma n.d. https://doi.org/10.1007/s00259-015-3135-1.

[21]     Giammarile F, Alazraki N, Aarsvold JN, Audisio RA, Glass E, Grant SF, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging 2013;40:1932–47. https://doi.org/10.1007/s00259-013-2544-2.

[22]     Giammarile F, Bozkurt MF, Cibula D, Pahisa J, Oyen WJ, Paredes P, et al. The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. Eur J Nucl Med Mol Imaging 2014;41:1463–77. https://doi.org/10.1007/s00259-014-2732-8.

[23]     Collarino A, Fuoco V, Garganese G, Pasciuto T, de Koster EJ, Florit A, Fragomeni SM, Zagaria L, Fragano A, Martinelli F, Ditto A, Seregni E, Scambia G, Raspagliesi F, Rufini V, Maccauro M. Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review. Gynecol Oncol. 2023 Mar;170:153-159. doi: 10.1016/j.ygyno.2023.01.011. Epub 2023 Jan 23. PMID: 36696819.

[24]     Pisano G, Wendler T, Valdés Olmos RA, Garganese G, Rietbergen DDD, Giammarile F, Vidal-Sicart S, Oonk MHM, Frumovitz M, Abu-Rustum NR, Scambia G, Rufini V, Collarino A. Molecular image-guided surgery in gynaecological cancer: where do we stand? Eur J Nucl Med Mol Imaging. 2024 Aug;51(10):3026-3039. doi: 10.1007/s00259-024-06604-1. Epub 2024 Jan 18. PMID: 38233609; PMCID: PMC11300493.

[25]     Brouwer OR, Albersen M, Parnham A, Protzel C, Pettaway CA, Ayres B, Antunes-Lopes T, Barreto L, Campi R, Crook J, Fernández-Pello S, Greco I, van der Heijden MS, Johnstone PAS, Kailavasan M, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Garcia-Perdomo HA, Rumble RB, Sachdeva A, Sakalis VI, Zapala Ł, Sánchez Martínez DF, Spiess PE, Tagawa ST. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. Eur Urol. 2023 Jun;83(6):548-560. doi: 10.1016/j.eururo.2023.02.027. Epub 2023 Mar 10. PMID: 36906413.

[26]     Morel A, Rousseau T, Ferrer L, Lacoste J, Nevoux P, Picot-Dilly E, Le Thiec M, Rusu D, Campion L, Rousseau C. Between Pathological Prostate Cancer Lymph Nodes and Sentinel Nodes: Which Information Is the Leader? Clin Nucl Med. 2024 Nov 1;49(11):e532-e537. doi: 10.1097/RLU.0000000000005270. Epub 2024 May 20. PMID: 38776066.

[27]     Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. British Journal of Haematology 2008;89:748–756. https://doi.org/10.1111/j.1365-2141.1995.tb08411.x.

[28]     Mostbeck A, Partsch H, Kahn P. Quantitative Isotopenlymphographie. In: Holzmann H, Altmeyer P, Hör G, Hahn K, editors. Dermatologie und Nuklearmedizin, Berlin, Heidelberg: Springer; 1985, p. 426–31. https://doi.org/10.1007/978-3-642-70279-2_54.

[29]     Brauer, W, Doeller, W, Gallowtsch, H, Gretener, S, Hoppe, H, Menzinger, G, et al. AG 3: Weiterführende Diagnostik 2017.

[30]     Hassanein AH, Maclellan RA, Grant FD, Greene AK. Diagnostic Accuracy of Lymphoscintigraphy for Lymphedema and Analysis of False-Negative Tests. Plast Reconstr Surg Glob Open 2017;5:e1396. https://doi.org/10.1097/GOX.0000000000001396.

[31]     Partsch H. Assessment of abnormal lymph drainage for the diagnosis of lymphedema by isotopic lymphangiography and by indirect lymphography. Clinics in Dermatology 1995;13:445–50. https://doi.org/10.1016/0738-081X(95)00085-T.